A Phase 3 interventional study of ZOSTAVAX™ and Placebo to ZOSTAVAX™ in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 3rd largest by enrollment, is one of 2 that started in 2015, is one of 9 in phase 3, and was the 24th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 2 started in 2015.
This study's enrollment of 882 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 5th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2015, is one of 14 in phase 3, and was the 27th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study evaluated immunogenicity, safety, and tolerability of ZOSTAVAX™ Vaccine (V211) administered concomitantly versus nonconcomitantly with Quadrivalent Influenza Virus vaccine (inactivated) in participants ≥50 years of age. The primary hypotheses tested 1) the noninferiority of concomitant versus nonconcomitant vaccination with regard to Varicella zoster virus (VZV) Geometric Mean Titer (GMT) antibody responses, 2) the acceptability of geometric mean fold rise in VZV antibody response after concomitant vaccination, and 3) the noninferiority of concomitant versus nonconcomitant vaccination with regard to influenza virus strain-specific GMT antibody responses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
Biological: ZOSTAVAX™ · Biological: Placebo to ZOSTAVAX™ · Biological: Influenza Vaccine
Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
Biological: ZOSTAVAX™ · Biological: Placebo to ZOSTAVAX™ · Biological: Influenza Vaccine
A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
Also known as: V211
A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
A single open-label administration of 0.5 mL intramuscular injection on Day 1
Also known as: Fluzone, Vaxigrip
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody
Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.
Time frame: Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)
Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers
Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.
Time frame: Baseline and 4 weeks after ZOSTAVAX™ vaccination (Week 4 for Concomitant group and Week 8 for Nonconcomitant group)
Geometric Mean Titers of H1N1-specific Influenza Virus Antibody
Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)
Geometric Mean Titers of H3N2-specific Influenza Virus Antibody
Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)
Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody
Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)
Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody
Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
Time frame: Baseline and 4 weeks after Influenza vaccination (Week 4)
| Milestone | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Started | 441 | 441 |
| Vaccinated on day 1 | 440 | 441 |
| Vaccinated at week 4 | 432 | 424 |
| Completed | 438 | 437 |
| Not completed | 3 | 4 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 3 |
Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.
| gpELISA units/mL | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Baseline, n=427, 409 | 206.0 (185.6 to 228.6) | 230.5 (208.4 to 255.0) |
| Week 4, n=409, 392 | 395.6 (363.7 to 430.4) | 482.0 (446.4 to 520.4) |
Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.
| Ratio of titers (Week 4 / Baseline) | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers | 1.9 (1.8 to 2.1) | 2.1 (1.9 to 2.2) |
Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
| Titer | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Baseline, n=426, 427 | 51.9 (45.4 to 59.3) | 50.1 (44.3 to 56.7) |
| Week 4, n=409, 405 | 207.3 (185.6 to 231.7) | 200.5 (180.3 to 222.9) |
Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
| Titer | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Baseline, n=426, 427 | 29.5 (26.2 to 33.3) | 31.1 (27.5 to 35.1) |
| Week 4, n=409, 405 | 298.8 (264.1 to 338.1) | 272.0 (241.6 to 306.1) |
Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
| Titer | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Baseline, n=426, 427 | 14.6 (13.3 to 16.1) | 12.6 (11.6 to 13.7) |
| Week 4, n=409, 405 | 46.7 (42.0 to 52.0) | 43.9 (39.7 to 48.6) |
Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.
| Titer | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Baseline, n=426, 427 | 11.2 (10.3 to 12.2) | 10.4 (9.6 to 11.2) |
| Week 4, n=409, 405 | 33.9 (30.5 to 37.7) | 32.3 (29.0 to 35.9) |
Collected over Up to 28 days after any vaccination (up to Week 8). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Concomitant Vaccination | — | 4/435 (0.9%) | 256/435 (58.9%) |
| Nonconcomitant Vaccination | — | 6/438 (1.4%) | 256/438 (58.4%) |
| Event | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Chest painGeneral disorders | 1/435 | 0/438 |
| Biliary colicHepatobiliary disorders | 1/435 | 0/438 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/435 | 0/438 |
| Ureteric cancer localNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/435 | 0/438 |
| Coronary artery diseaseCardiac disorders | 0/435 | 1/438 |
| Gastrointestinal toxicityGastrointestinal disorders | 0/435 | 1/438 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/435 | 1/438 |
| OesophagitisGastrointestinal disorders | 0/435 | 1/438 |
| CholecystitisHepatobiliary disorders | 0/435 | 1/438 |
| Cerebrovascular accidentNervous system disorders | 0/435 | 1/438 |
| Event | Concomitant Vaccination | Nonconcomitant Vaccination |
|---|---|---|
| Injection site painGeneral disorders | 209/435 | 211/438 |
| Injection site erythemaGeneral disorders | 153/435 | 134/438 |
| Injection site swellingGeneral disorders | 102/435 | 109/438 |
| Injection site pruritusGeneral disorders | 33/435 | 32/438 |
Participants are included as randomized
| Age, Continuous(Years) | Concomitant Vaccination | Nonconcomitant Vaccination | Total |
|---|---|---|---|
| Mean | 60.8 ± 7.2 | 61.3 ± 7.7 | 61.0 ± 7.5 |
| Sex: Female, Male(Participants) | Concomitant Vaccination | Nonconcomitant Vaccination | Total |
|---|---|---|---|
| Female | 266 | 262 | 528 |
| Male | 174 | 180 | 354 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2015 to primary completion in Jan 2016, 4 months.
Results were first posted in Feb 2017, 1 year after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 4 months is below that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine